UWELL BIOPHARMA INC.
Update：2025/12/03
Industries
Main Industry
Health Care
Main Product/Service
Our therapy involves genetically modifying a patient’s T cells outside the patient’s body, transforming the T cells to express chimeric antigen receptors (CARs), and then reinfusing the engineered T cells back into the patient.
Founded Year
2020
Unified Business No.
83304134
Status
Active
Number of Employees
23
Total Paid-in
Capital
200,000,000 (NT$)
Location of Company
Taiwan
, New Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
UWELL BioPharma, is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotheraputics designed to harness the power of a patient’s own immune system to target and eradicate cancer cells. We do this using our engineered autologous cell therapy, which we believe is a transformational approach to the treatment of cancer. Our therapy involves genetically modifying a patient’s T cells outside the patient’s body, transforming the T cells to express chimeric antigen receptors (CARs), and then reinfusing the engineered T cells back into the patient. CARs can recognize native cancer antigens that are part of an intact protein presented on the cancer cell surface. UWELL BioPharma is a cellular therapy company based in New Taipei City, Taiwan. UWELL has a strong management team and a team of professional and experienced scientists who are developing cutting edge technology to help fight cancer. Uwell Has a strong collaboration and close interaction with excellent clinical teams and partners in Taiwan and China, as well as in Malaysia. UWELL has generated and advanced a broad portfolio of product candidates to target hematological tumors.
